text size - +

spacer

Mesothelioma Doctors / Physicians


Daniel Sterman, M.D.

Title
Assistant Professor of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA
Phone
(215) 614-0984
Education
  1. A.B., European History, Brown University, 1985
  2. M.D., Cornell University Medical College, 1989
Residency
Internal Medicine, Hospital of the University of Pennsylvania
Fellowship
Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania
Board Certifications
  1. Internal Medicine
  2. Pulmonary Medicine
  3. Critical Care Medicine
Clinical Expertise
Thoracic Oncology, specifically lung cancer, malignant mesothelioma and mediastinal tumors
Website
Biography/CV (will open new window)

Dr. Sterman received his A.B. in European History from Brown University in 1985, and his M.D. from Cornell University Medical College in 1989. He then pursued his Internship and Residency in Internal Medicine at the Hospital of the University of Pennsylvania from 1989-1992; followed by an Instructorship in Emergency Medicine also at HUP from 1992-93. Subsequently, Dr. Sterman received fellowship training in Pulmonary and Critical Care Medicine at the University of Pennsylvania Medical Center from 1993-1997. While a fellow, he received advanced training in Interventional Bronchoscopy and Pleuroscopy with Dr. Michael Unger at Pennsylvania Hospital, and with Dr. Larry Kaiser of the HUP Division of General Thoracic Surgery. In addition, he was a Postdoctoral Research Fellow in the Thoracic Oncology Research Laboratory of the University of Pennsylvania Medical Center under the tutelage of Dr. Steven Albelda. After spending two years in the Thoracic Oncology Laboratories working with Drs. Albelda and Kaiser, he joined the faculty at PENN in 1997 as an Assistant Professor of Medicine in the Pulmonary Division and was the recipient of a NIH Clinical Associate Physician Award. Dr. Sterman is board certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine.

Dr. Sterman is currently Associate Professor of Medicine and Associate Professor of Medicine in Surgery, and the Director of the PENN Interventional Pulmonology Program and Clinical Director of the Thoracic Oncology Gene Therapy Program of the Center for Lung Cancer and Related Disorders of the University of Pennsylvania Medical Center. Dr. Sterman has advanced training in the following techniques: flexible and rigid bronchoscopy; balloon bronchoplasty, endobronchial stent placement (metal, hybrid, and silicone), endobronchial brachytherapy, photodynamic therapy, auto-fluorescence bronchoscopy (LIFE), transbronchial needle aspiration/biopsy, bronchoscopic electrosurgery (including APC), endobronchial ultrasound (radial and convex probe), percutaneous tracheotomy, and pleuroscopy. His clinical interests are related to the treatment of thoracic malignancies, specifically as they apply to the synergy of molecular medicine and novel technologies in Interventional Pulmonology. His research interests are in the translation of laboratory discoveries from the bench to the bedside: conducting human clinical trials of gene therapy and vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies.

Dr. Sterman is the lead clinical investigators in the multidisciplinary Thoracic Oncology Research Group at Penn and has been the Principal Investigator of Project 1 (Clinical Trials Project) for this NCI Program Project Grant since 1998. He is currently the sponsor and Principal Investigator of the ongoing Ad.IFN-beta gene therapy trial aimed at cancer patients with mesothelioma and metastatic pleural disease. In addition, he has led a number of other industry-sponsored cancer clinical trials, all with extramural funding. He served as the Principal Investigator at Penn of a series of Multicenter Phase II Clinical Trials, sponsored by Cell Genesys, Inc, evaluating patient-specific lung cancer vaccines. He is currently participating in a multicenter, randomized, double-blinded Phase III clinical trial of a recombinant MUC-1 vaccine for Stage III NSCLC patients with stable/responding disease status post definitive chemoradiotherapy.

More recently, in collaboration with other members of the clinical trials group from the Thoracic Oncology Research Laboratory, composed of members from Pulmonary Medicine, Medical Oncology, and Thoracic Surgery, Dr. Sterman is conducting a series of trials focused on the concept of genetic immunotherapy for thoracic malignancies (bronchogenic, carcinoma, mesothelioma, metastatic pleural disease). The hallmark of this program is our ongoing Phase I clinical trial of intrapleural adenovirus mediated human interferon gene transfer for patients with pleural malignancies. Dr. Sterman and colleagues are developing trial involving delivery of the interferon-alpha gene via adenoviral vector, with the goal of combining this experimental treatment with standard combination chemotherapy, based upon success in pre-clinical studies.

In addition, Dr. Sterman and colleagues will be initiating a multicenter Phase I trial of intravenous delivery of a recombinant, attenuated Listeria monocytogenes bacterial vector expressing the gene for human Mesothelin, a cell surface protein expressed on 50% of non-small cell lung cancers and nearly 100% of mesotheliomas. He is also developing, with Dr. Steven Albelda, a clinical trial of bronchoscopic injection of a recombinant, replication competent Vaccinia viral vector expressing the human GM-CSF gene with patients with refractory small cell and non-small cell carcinoma of the lung, which will be enrolling patients in 2008.

Dr. Sterman has also been involved in pioneering clinical research projects aimed at developing advanced bronchoscopic techniques to treat diseases such as tracheomalacia, severe asthma, and emphysema.

Related Information

Rapid Response

Our staff is available to answer your questions, point you in the right direction or provide additional information. Feel free to submit questions or comments below.
Name:
Phone:
Email:
Summary:
How did you Find Us?

Email Alerts

100 Questions & Answers

100 Questions & AnswersMesothelioma is a serious cancer that occurs in individuals exposed to asbestos. Contact us now and we will send you a complementary copy of “100 Questions & Answers About Mesothelioma” by Harvey I. Pass.
Clinical Trails

Recipe of the week

Winter Soup more

Attorney Advertising - Legal Disclaimer
Speaking with an Attorney? Your Legal Rights
** Persons depicted in any pictures are actors. They are not clients. **



Copyright © 2007 - Belluck & Fox, Attorneys at Law - Mesothelioma Lawyers.
Mesothelioma Attorneys, Asbestos Lawyers – Mesothelioma Information, Diagnosis, Symptoms, Medical Staging, Prognosis, Treatment, Clinical Trial,
Asbestos Exposure, Asbestosis, Lung Cancer, Malignant Pleural Mesothelioma, Asbestos & The Navy, Health, Surgery, ChemotherapyRadiation, Gene Therapy,
Photodynamic Therapy, Immunotherapy

Site by Consultwebs.com: Law Firm Website Designers / Personal Injury Lawyer Marketing